Vous n'êtes pas identifié (connexion)

Centre de recherche

JEUDI 30 MARS

Geneviève Asselin et Martin Bussière, UETMIS, CHU de Québec - Université Laval

Conférence

Les bains de chlorhexidine aux soins intensifs : évaluation de l'efficacité et de l'innocuité

Calendrier >

BOTTIN

Gary Kobinger

Formation
à venir

Aucune offre active

Autres opportunités de carrière
Axe principal
Maladies infectieuses et immunitaires
Adresse(s)
Centre Hospitalier de l'Université Laval (CHUL)
2705, boulevard Laurier
RC-709
Québec (Québec)
CANADA G1V 4G2

Téléphone(s)
+1 418-525-4444, poste 47772
Télécopieur(s)
Courriel(s)
Gary.Kobinger@crchudequebec.ulaval.ca

Projet(s) de recherche actif(s)

Aucun projet de recherche à afficher

Publications récentes (voir toutes les publications de ce chercheur)

Biava M, Caglioti C, Bordi L, Castilletti C, Colavita F, Quartu S, Nicastri E, Lauria FN, Petrosillo N, Lanini S, Hoenen T, Kobinger G, Zumla A, Di Caro A, Ippolito G, Capobianchi MR, Lalle E. Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient. PLoS pathogens,  2017. 13: e1006065
Saphire EO, Dye JM, Kobinger GP, Zeitlin L, Chandran K, Garry RF. How to turn competitors into collaborators. Nature,  2017. 541: 283-285
Ludtke A, Ruibal P, Wozniak DM, Pallasch E, Wurr S, Bockholt S, Gomez-Medina S, Qiu X, Kobinger GP, Rodriguez E, Gunther S, Krasemann S, Idoyaga J, Oestereich L, Munoz-Fontela C. Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination. Scientific reports,  2017. Epub
de Wit E, Falzarano D, Onyango C, Rosenke K, Marzi A, Ochieng M, Juma B, Fischer RJ, Prescott JB, Safronetz D, Omballa V, Owuor C, Hoenen T, Groseth A, van Doremalen N, Zemtsova G, Self J, Bushmaker T, McNally K, Rowe T, Emery SL, Feldmann F, Williamson B, Nyenswah TG, Grolla A, Strong JE, Kobinger G, Stroeher U, Rayfield M, Bolay FK, Zoon KC, Stassijns J, Tampellini L, de Smet M, Nichol ST, Fields B, Sprecher A, Feldmann H, Massaquoi M, Munster VJ. The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak. Emerging infectious diseases,  2016. 22: 323-6
McCarthy SD, Majchrzak-Kita B, Racine T, Kozlowski HN, Baker DP, Hoenen T, Kobinger GP, Fish EN, Branch DR. A Rapid Screening Assay Identifies Monotherapy with Interferon-ss and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS neglected tropical diseases,  2016. 10: e0004364
Vu H, Shulenin S, Grolla A, Audet J, He S, Kobinger G, Unfer RC, Warfield KL, Aman MJ, Holtsberg FW. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. Antiviral research,  2016. 126: 55-61
Qiu X, Audet J, Lv M, He S, Wong G, Wei H, Luo L, Fernando L, Kroeker A, Bovendo HF, Bello A, Li F, Ye P, Jacobs M, Ippolito G, Saphire EO, Bi S, Shen B, Gao GF, Zeitlin L, Feng J, Zhang B, Kobinger GP. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Science translational medicine,  2016. 8: 329ra33
Zhang X, Ao Z, Bello A, Ran X, Liu S, Wigle J, Kobinger G, Yao X. Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection. Antiviral research,  2016. Epub
Dietzel E, Kolesnikova L, Sawatsky B, Heiner A, Weis M, Kobinger GP, Becker S, von Messling V, Maisner A. Nipah Virus Matrix Protein Influences Fusogenicity and Is Essential for Particle Infectivity and Stability. Journal of virology,  2016. 90: 2514-22
Mendoza EJ, Qiu X, Kobinger GP. Progression of Ebola Therapeutics During the 2014-2015 Outbreak. Trends in molecular medicine,  2016. 22: 164-73
© 2017 Tous droits réservés Centre de recherche du CHU de Québec